Law & Governance
Roger Chafe, Anthony Culyer, Mark Dobrow, Peter C. Coyte, Carol Sawka, Susan O'Reilly, Kara Laing, Maureen Trudeau, Sharon Smith, Jeffrey S. Hoch, Steve Morgan, Stuart Peacock, Rick Abbott and Terrence Sullivan
[This article was originally published in Healthcare Policy 6(3)]
Objective: To examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs.
Data Sources/Study Design: We surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs.
Principal Findings: While there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs.
Conclusions: The study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.
Be the first to comment on this!
This article is for subscribers only. To view the entire article
Note: Please enter a display name. Your email address will not be publically displayed